Biobank中文Project inquiry
R&D ServicesNavigation menu
R&D ServicesModels & ProductsApplicationsTechnologyEvidence & ResourcesHow We WorkAbout TRiCBIONews & EventsBiobankProject inquiry中文

Solutions & R&D services

Human organoid R&D services

From target discovery to candidate evaluation and safety, choose models and assays around your program goal, modality and available samples.

Discovery & validationCandidate evaluationSafety & drug delivery

Discovery research

Discovery & validation

Screen or perturb targets in relevant human models, then examine phenotype and pathway changes.

4 services
Organoid target discovery connecting genetic perturbation, molecular confirmation, functional phenotype and treatment responsePDO 1.0 + PDO 2.0 · genetic-library screening01

Organoid target discovery & functional genomics

Discover genetic dependencies through library screening in PDO 1.0 and PDO 2.0. Validate targets through tumor, microenvironment and treatment-response readouts.

↗Organoid target-validation workflow from model selection and delivery through genetic perturbation, molecular confirmation and functional phenotyping02

Target validation & mechanism studies

Test candidate targets in human organoids through disease phenotypes, molecular changes and treatment response.

↗H&E histology and CD31/HEP-1 immunohistochemistry in HCC source tissue and PDOHCC tissue & PDO · H&E, CD31 & HEP-103

Mechanism & biomarkers

Link tissue, functional and molecular results to treatment response and prioritize biomarker candidates for validation.

↗Two GIST morphology groups comparing tissue-derived cultures, source-tissue H&E and culture H&E04

Custom model development

Develop a model and assay plan for specialized tissues, rare diseases or complex co-cultures, starting from the samples and endpoints available to your program.

↗

Candidate studies

Candidate evaluation

Compare single agents, dose responses and combinations with modality-relevant efficacy, immune and mechanism readouts.

4 services
Dose-related morphology in two breast cancer PDO models from a representative plate-based ADC study01

Organoid efficacy screening

Compare single agents and combinations in tumor PDOs and other selected human organoid models to identify dose responses and differences across models.

↗Cell-death flow readouts under control and immune-checkpoint-blockade conditions in PDO 2.002

Immuno-oncology

Evaluate immune activation and tumor-cell killing in PDO 2.0 / ALI models or immune co-cultures, with tissue imaging and functional assays tailored to your candidate.

↗PDAC source tissue, PDO bright-field, PDO histology and CK19/CD3 immunofluorescencePDAC PDO 2.0 · CK19 and CD3 tissue profiling03

Antibody, multispecific & T-cell engager (TCE) studies

Compare tumor-cell killing, immune activation and cytokine changes for antibody, multispecific and TCE candidates in human tumor organoids and suitable immune co-cultures.

↗Morphology and dose response after ADC treatment in two breast cancer PDO models04

ADC research

Combine target expression, spatial distribution, cytotoxicity and bystander-effect readouts in an organoid study matched to the candidate ADC.

↗

Safety & drug delivery

Safety & drug delivery

Examine in vitro injury-response windows, with barrier or transport assays where the study calls for them.

3 services
Human kidney organoid bright-field morphology before and 24/48 hours after doxorubicin exposure01

Safety & toxicology

Compare dose- and exposure-related responses in relevant normal-tissue organoids, using morphology, function and injury markers to investigate organ risk.

↗Bright-field, AT1, AT2, DAPI and merged views of lung organoids under normal and LPS conditionsNormal lung · LPS injuryKidney injury-related qPCR readouts after cisplatin exposure in H9-derived kidney organoidsHuman kidney organoid · cisplatin response02

Multi-organ safety in human organoids

Compare normal kidney, lung and GI organoids with adjacent non-tumor liver or other relevant models in a coordinated exposure design to rank organ risks and focus follow-up safety studies.

↗Bright-field and FITC microscopy in control and inflammation-challenged human intestinal organoidsHuman intestinal organoid · inflammation & barrier03

Drug delivery & barrier permeability

Assess barrier integrity, injury and repair, then develop permeability or candidate-transport assays for the relevant tissue system.

↗
Not sure where to start?

Tell us about your candidate, sample context and program priorities; our scientists will recommend the model, assay panel and study plan.

Discuss the study objective